Blockchain Registration Transaction Record

Regentis Biomaterials Gets EU Nod for Next-Gen GelrinC Manufacturing

Regentis Biomaterials receives European approval for next-gen GelrinC manufacturing process, boosting yield by 400%. GelrinC is a cell-free hydrogel implant for cartilage repair, targeting a $3B market.

This approval not only boosts Regentis's production capacity by 400% but also paves the way for the commercial launch of GelrinC in Europe, offering a minimally invasive, off-the-shelf solution for cartilage repair. For patients suffering from knee cartilage damage, this means potential access to a treatment that regenerates tissue without the need for cell extraction or multiple surgeries. The improved manufacturing process could lower costs and increase availability, addressing a large unmet need in orthopedics. Investors should note the potential market opportunity in the $3 billion U.S. cartilage repair market, where no comparable off-the-shelf product exists.